Abstract
BackgroundTo evaluate the clinical outcomes of patients treated with 3D conformal Hypo-fractionated, deep Inspiratory breath-hold (DIBH), Partial breast radiotherapy, termed “HIP.” HIP was implemented to merge the schedule of once-daily breast hypofractionation with partial breast treatment.MethodsWe identified 38 breast cancers in 37 patients from 2013 to 2014 treated at our institution with HIP following lumpectomy for early stage breast cancer. Patients received a hypo-fractionated course (≤ 20 fractions) of once daily radiation to the partial breast (lumpectomy cavity + margin) utilizing DIBH regardless of laterality. Clinical and treatment-related characteristics were obtained, including target volume and organ at risk (OAR) dosimetric characteristics. Patients were followed clinically and with at least yearly mammograms for up to 36 months (range 5–36 months). Acute and late toxicity was scored using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03.ResultsPatients received a median dose of 42.56 Gy in 16 Fractions (Fx) (range 40.05–53.2 Gy; and 15–20 Fx). OAR doses were low, with a mean heart dose of 0.37 Gy, an ipsilateral lung V20 mean of 4%, and a contralateral lung V5 of 1%. Acute toxicity (≤ grade 2) was present in 79% (n = 30) of the cases, with dermatitis being the most common finding (63%). Late grade 1–2 toxicity was present in 42% (n = 16) of the cases, with hyperpigmentation being the most common finding (n = 9). There were no severe acute or late toxicities (≥ grade 3). At a median follow up of 21 months, there were no local, regional, or distant failures.ConclusionsWe report limited toxicity in this low risk cohort of patients with early stage breast cancer treated with HIP, a unique and logical combination of 3-D conformal external beam radiotherapy, moderate hypo-fractionation, and DIBH.
Highlights
To evaluate the clinical outcomes of patients treated with 3D conformal Hypo-fractionated, deep Inspiratory breath-hold (DIBH), Partial breast radiotherapy, termed “HIP.” HIP was implemented to merge the schedule of once-daily breast hypofractionation with partial breast treatment
The use of adjuvant whole breast irradiation (WBI) following breast conservation surgery has been demonstrated in numerous clinical trials to reduce the rates of ipsilateral breast tumor recurrence (IBTR) by over 50% compared to lumpectomy alone [4, 5]
With strong clinical evidence to support its use, hypo-fractionation has become increasingly popular for patients in Canada and the United States for early stage breast cancer [2, 6, 7]
Summary
To evaluate the clinical outcomes of patients treated with 3D conformal Hypo-fractionated, deep Inspiratory breath-hold (DIBH), Partial breast radiotherapy, termed “HIP.” HIP was implemented to merge the schedule of once-daily breast hypofractionation with partial breast treatment. Breast conservation therapy (BCT), which includes lumpectomy (surgical resection of the tumor alone) and radiation therapy (RT), is the nationally accepted standard treatment approach for early stage breast cancer and is used in 70% of such patients [2, 3]. The use of adjuvant whole breast irradiation (WBI) following breast conservation surgery has been demonstrated in numerous clinical trials to reduce the rates of ipsilateral breast tumor recurrence (IBTR) by over 50% compared to lumpectomy alone [4, 5]. With strong clinical evidence to support its use, hypo-fractionation has become increasingly popular for patients in Canada and the United States for early stage breast cancer [2, 6, 7]. There is sufficient evidence from randomized clinical trials that hypo-fractionated RT is considered the national preferred option for the majority of patients [6, 8, 9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
